Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company.

BOSTON (PRWEB)
May 14, 2020

DermBiont, a clinical stage microbiome biotechnology company developing topical live biotherapeutics, is pleased to announce that Mr. Steven Basta has been appointed to the company’s board of directors, effective immediately.

“Having led multiple therapeutics and healthcare organizations as CEO, Steven brings an exceptional track record as an executive to the Board of Directors here at DermBiont, the world’s leading skin microbiome therapeutics company. Our entire leadership team is excited to benefit from his experience as we continue to advance our discovery programs and products in development,” said Karl Beutner, CEO of DermBiont.

“DermBiont has built an incredible platform and culture that enables the company to discover and advance microbial therapeutics through the clinic much faster and more efficiently than traditional therapeutics,” said Steven Basta. “I look forward to working with Karl and the leadership team. The entire DermBiont organization is committed to developing novel therapeutics that treat skin diseases at their root cause, a dysbiosis of the cutaneous microbiome.”

Mr. Basta most recently served as the President and CEO of Menlo Therapeutics, a dermatology therapeutics development company. Mr. Basta previously served as CEO at AlterG Inc, BioForm medical (acquired by Merz), Merz Aesthetics, and Gliatech. He currently sits on the board of Menlo Therapeutics, and serves as the Chairman of the Board of Viveve Medical.

DermBiont’s other current board members are: Karl Beutner, CEO, DermBiont (formerly CMO of Anacor, sold to Pfizer for $5.2B in 2016); Wilder Ramsey, Partner, Toba Capital; Nichola Eliovits, Managing Partner, Olive Tree Capital.

About DermBiont

DermBiont is the world’s leading dermatology company leveraging skin microbiome therapeutics (live biotherapeutics) to treat the root cause of skin diseases. In addition to the company’s lead product in development to treat Onychomycosis and Atopic Dermatitis, DBI-001, the company is advancing four other clinical assets across a wide range of skin diseases caused by a dysbiosis of the microbiome. The company’s discovery capabilities are powered by a proprietary computational biology platform enabling the rapid discovery of hits against pathogens from a curated library of thousands of microbes isolated from human skin and one of the world’s largest data sets of Nextgen sequencing of the human microbiome across healthy and diseased skin.

Send all inquiries to: press@dermbiont.com

http://www.dermbiont.com

Share article on social media or email:

sEMG biofeedback is highly motivating for both children and adults and the powerful engagement created, sets the stage for new movement habits and positive neuroplastic changes.

MONTREAL, Quebec (PRWEB)
May 14, 2020

In an upcoming live webinar, Pia Stampe, PT, DPT will discuss sEMG Biofeedback as an effective intervention tool in neuro-rehabilitation. sEMG Biofeedback is an under-utilized intervention for pediatric and adult patients with neurological impairments. Dr. Stampe will show the immediate effect of using biofeedback to create awareness and efficient muscle recruitment/relaxation and how this results in rapid functional improvements. sEMG Biofeedback is highly motivating for both children and adults and the powerful engagement created, sets the stage for new movement habits and positive neuroplastic changes. This webinar will dispel the common perception of sEMG Biofeedback being complicated and difficult to use as a rehabilitation tool.

sEMG Biofeedback in NeuroRehabilitation: The power of the “a-ha” moments

Presenter: Pia Stampe, PT, DPT

Date: May 20, 2020

Time: 1:00-2:00 pm EDT

Click here to register.

About Pia Stampe, PT

Pia Stampe (PT, DPT), is the owner and founder of KeytoCP Intensives, formerly Step by Step CP Intensives. Pia is a pediatric physical therapist with more than 35 years of experience working with children with cerebral palsy. She graduated from PT education in Copenhagen, Denmark in 1981 and earned her Doctor of Physical Therapy degree from AT Still University in 2008. Pia has completed extensive continuing education and has teaching experience in pediatrics/neurology, coaching and use of EMG biofeedback, neuromuscular stimulation, and functional electrical stimulation. Pia has worked closely with Karen Pape, MD as the systematic, intensive model used at KeytoCP was developed.

About Thought Technology Ltd.

Founded in 1975, Thought Technology is the world’s leading biofeedback and physiological instrument manufacturer. Its products are used as an essential part of many therapeutic treatments and clinical assessment protocols in over 85 countries and are used by tens of thousands of clinicians in thousands of medical institutions.

Always supportive of new research and development ideas, Thought Technology Ltd. has encouraged a number of special interest groups and clinicians to create cutting edge applications for its instrumentation. Thought Technology Ltd. equipment is now being used in telemedicine, web-based monitoring and biofeedback, sports training, research in human-machine interface, physiology-driven multimedia environments and virtual reality. Constantly striving to improve the quality of the products and services, TTL has obtained, and maintains, ISO 13485, and CE certification for the organization and products.

Share article on social media or email:

Clear Labs’ fully- automated NGS platform with its flexible and robust architecture has allowed the company to develop a turn-key genomics-based assay that hasn’t before existed in the clinical space and will provide a new layer of COVID-19 testing never before possible.

MENLO PARK, Calif. (PRWEB)
May 14, 2020

Clear Labs, providers of the only automated and intelligent diagnostic NGS platform, today announced the raise of a $18M strategic round of funding led by Redmile Group, as well as existing investors including Wing VC, Menlo Ventures, Tyson Ventures, Khosla Ventures, GV, Felicis Ventures, and HBM Genomics. To date, Clear Labs has raised $62M.

In addition to supporting ongoing commercialization of the company’s food safety platform, Clear Safety, the funds will be used to leverage the company’s underlying Next Generation Sequencing (NGS) technology in the clinical market, specifically to enhance the availability and quality of COVID-19 diagnostic tests.

Experts agree that the limitations of COVID-19 testing have been a large contributing factor to the spread of the virus in the United States. Aside from an initial shortage of tests, the existing gold standard diagnostic screening shows 10-30% false negative rates. With such a high rate of false negatives, the other concern is when a symptomatic patient has a negative test result. Symptoms of COVID-19 are often similar in nature to the common cold or flu, making it difficult to decipher if a test result is a false or true negative. Additionally, testing for asymptomatic patients is nearly nonexistent, preventing officials from fully understanding how the virus has spread.

While the lack of ability to track infection clusters and transmission routes presents serious challenges, current mainstream diagnostic tests (including qPCR, and LAMP) are also unable to follow emerging mutations that could create different versions of the virus in the future. This could lead to problematic resistance against new and emerging pharmaceutical interventions intended to target COVID-19.

Clear Labs’ fully- automated NGS platform with its flexible and robust architecture has allowed the company to develop a turn-key genomics-based assay that hasn’t before existed in the clinical space and will provide a new layer of COVID-19 testing never before possible.

“We saw an important opportunity to help stop the global spread of COVID-19 with the platform we’ve developed over the last 6 years. Our technology, while built originally for food safety, has become a powerful genomic tool with unmatched cost, time-to-results, and ease of use that can provide great benefit to the clinical market,” said Sasan Amini “Our genomics-based assay not only provides significantly higher rates of accuracy for detection of SARS-CoV-2, it prepares us for the future of the virus. Clear Labs’ technology will be able to keep up with the rapid evolution of viral RNA so that labs, hospitals and even companies developing therapeutics have up-to-date molecular data to power intervention and large-scale epidemiology.”

Clear Labs’ novel characterizing diagnostic provides hospitals and clinical diagnostic labs with:

Superior Diagnostic

• Accuracy – effectively eliminates false positives and significantly minimizes false negatives
• Automation – improves reproducibility, reduces human labor and potential for error – all while providing the highest possible biosafety for operators
• Cost Savings – Clear Labs’ platform is the most cost-effective sequencing solution available on the market, and enables the highest reimbursement rates
• Turnaround Time – end-to-end sample to answer is 8 hours
• Advanced Bioinformatics – provides automated, cloud-based, scalable computational power with no bioinformaticians required

Powerful Genomic Surveillance

• Non-binary Results – our surveillance tool allows labs to differentiate RNA viruses
• Drive Intervention – monitor evolution of viral genes that are therapeutic targets
• Empower Large-Scale Epidemiology – identify infection clusters and transmission routes
• Recognize Co-Infections – identify cases of co-infection
• No Additional Cost & Time – all genomic surveillance features are included with screening

“Clear Labs previously developed the first and only high quality, rapid and automated pathogen sequencing system, now in regulated commercial use for food safety testing. Based on feedback from leading experts, Clear Labs rapidly developed a SARS-CoV-2 testing system to address the tremendous global need,” said Greg Yap, Partner at Menlo Ventures. “Clear Labs next-gen sequencing, sample-to-answer system has the potential to improve SARS-CoV-2 testing accuracy and availability worldwide”.

Clear Labs’ platform leverages the latest technology in molecular testing, proprietary bioinformatics software, and robotics. It also includes an unprecedented level of automation and robotics to reduce human labor and errors. Clear Labs’ AI and machine learning provide additional insights and trends, allowing researchers, epidemiologists and clinical labs to track infection clusters, drive intervention, and monitor the evolution of viral genes that are therapeutic targets.

“Our team has been working diligently and tirelessly to deploy our technology to help with COVID-19,” said Ramin Khaksar, VP of R&D. “We hope that the power of our platform and what we’ve built will help us all better understand and act on this virus. We’re grateful to everyone who has been on the front lines, and we’re honored to do our part to help.”

Clear Labs is already working with leading hospitals, universities, and labs on deploying the test and expect to receive the FDA Emergency Use Authorization (EUA) within the coming days.

To learn more about Clear Labs and to pre-register for its novel characterizing diagnostic, please visit: http://www.clearlabs.com/covid-19.

About Clear Labs

Clear Labs is the only automated and intelligent diagnostic NGS platform. We help our customers capitalize on a new era of technology by seamlessly integrating DNA sequencing, bioinformatics, and robotics. The result democratizes genomics within settings never before possible.

With these capabilities, Clear Labs has become a prominent and credible platform for safeguarding the global food supply and enhancing preventative food safety management systems. Now, we are leveraging our novel genomics platform for deep COVID-19 characterizing diagnostics.

The world’s largest brands and organizations have implemented and are already realizing the advantages of the Clear Labs’ system.

To learn more, please visit: http://www.clearlabs.com/.

Share article on social media or email:

T1 Payments Donates to Nevada Community Foundation to Assist Frontline Workers

“With our donation, we hope to keep our frontline workers safe so they can return home to their families every day,” said a T1 Payments representative. “We need to do our best to support and protect all frontline workers from the COVID-19 pandemic.”

LAS VEGAS (PRWEB)
May 14, 2020

T1 Payments, a leader in high-risk merchant processing, is donating to the Nevada Community Foundation’s COVID-19 Emergency Response Fund in an effort to assist with the State’s response, relief, and recovery efforts during the Coronavirus (COVID-19) pandemic.

Nevada Community Foundation and Nevada COVID-19 Response, Relief, and Recovery Task Force are partnering to support the state of Nevada, distributing supplies to the areas of greatest need. The fund focuses on providing first responders and healthcare providers with personal protective equipment (PPE), ventilators, testing supplies, and other medical supplies.

T1 Payments’ contribution will assist Nevada’s medical community and first responders, providing critical resources needed to keep health care workers and other frontline workers protected. This will help reduce pressure on medical capacity, supporting the most essential members and true heroes in the community.

“With our donation, we hope to keep our frontline workers safe so they can return home to their families every day,” said a T1 Payments representative. “We need to do our best to support and protect all frontline workers from the COVID-19 pandemic.”

T1 Payments is proud to give back to the medical community during this time of uncertainty. With their ongoing donations and support, T1 Payments hopes Nevada recovers soon from the COVID-19 pandemic.

T1 Payments continues to increase awareness and fund programs in effort to bring everyone in the Nevada community together.

For more information about how to donate to help frontline workers impacted by the COVID-19 pandemic, visit the Nevada Community Foundation website.

More about T1 Payments:

T1 Payments is a high-risk merchant processing company that is flexible, transparent, and scalable. T1 Payments’ secure gateway and integrated shopping cart solutions are compliant with all Payment Card Industry Data Security Standards (PCI DSS).

In addition to high-risk merchant processing services, T1 Payments stays involved in the community through its ongoing donations and sponsorships. To learn more about the nonprofits T1 Payments supports, visit T1 Payments Community Involvement page on their website.

For more information, please visit the T1 Payments website (https://t1payments.com/) or call 1-866-518-2216.

Share article on social media or email:

“Ingo Chakravarty is an accomplished and passionate leader in the healthcare and medical diagnostics fields, and he will be a tremendously valuable addition to Mesa Biotech’s executive team as the company expands its product line to respond to the COVID-19 pandemic.”

SOUTH RIDING, Va. (PRWEB)
May 14, 2020

Slone Partners, a nationwide executive search firm for life sciences, biotechnology, and diagnostics companies, has announced the placement of Ingo Chakravarty as President and Chief Executive Officer (CEO) of Mesa Biotech. Chakravarty assumes leadership of the company less than two months after it received Emergency Use Authorization (EUA) from the Federal Drug Administration (FDA) to market its 30-minute point-of-care (POC) molecular SARS-CoV-2 test.

Chakravarty joins Mesa Biotech with more than 25 years of experience and a proven track record in capital formation and building and leading high-performing organizations in the healthcare industry. He most recently served as President and CEO of NAVICAN Genomics after spending nearly two decades building global businesses in the oncology and infectious disease market. He has held senior leadership positions at GenMark Diagnostics, Gen-Probe, Roche, and Ventana Medical Systems.

Mesa Biotech designs, develops, manufactures and commercializes next generation molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Similar to Mesa Biotech’s commercially available tests for influenza and RSV, the new rapid Accula™ SARS-CoV-2 test provides actionable, laboratory-quality results at POC with greater sensitivity and specificity than traditional infectious disease rapid immunoassay tests.

“Ingo Chakravarty is an accomplished and passionate leader in the healthcare and medical diagnostics fields, and he will be a tremendously valuable addition to Mesa Biotech’s executive team as the company expands its product line to respond to the COVID-19 pandemic,” said Slone Partners CEO Leslie Loveless.

Dr. William Brody, Chairman of the Board of Mesa Biotech, said, “Mesa Biotech has enhanced its market position with the launch of two FDA cleared products for Flu A/ Flu B and RSV, and the more recent Emergency Use Authorization (EUA) for the 30-minute point-of-care Accula SARS-CoV-2 test. Entering our next phase of growth, Mr. Chakravarty is the right person, at the right time, to lead Mesa Biotech.”

“It is remarkable what Mesa Biotech has achieved over the past decade,” said Chakravarty. “I am grateful for the opportunity to be part of such a dedicated, high performing team. Together we will seize the opportunity and be part of the global response to the current and any future infectious disease challenges that require us to quickly generate the most accurate diagnostic data possible – anytime, anywhere.”

ABOUT SLONE PARTNERS

Slone Partners delivers the leaders who build amazing scientific healthcare organizations – People Are Our Science®. Since 2000, Slone Partners specializes in delivering world-class C-suite leadership, executive, and upper management talent to the most promising and established life sciences, diagnostics, precision medicine, CRO, and laboratory services companies. With coast-to-coast presence in the most active healthcare industry hubs of Boston, San Francisco, Los Angeles, San Diego, Austin, Research Triangle Park NC, and Washington DC, Slone Partners uniquely and precisely provides an array of executive search and advisory services to innovative scientific healthcare companies. To learn more about Slone Partners’ value proposition and processes, visit http://www.slonepartners.com or call 888.784.3422.

ABOUT MESA BIOTECH INC.

Mesa Biotech designs, develops, manufactures and commercializes next generation rapid molecular diagnostic tests, bringing the superior diagnostic performance of nucleic acid PCR amplification to the point-of-care. Mesa Biotech’s Accula™ Flu A/Flu B and RSV tests have obtained CE Mark in the EU and 510(k) clearance and Clinical Laboratory Improvements Amendments (CLIA) waiver from the U.S. Food and Drug Administration (FDA). Both products are distributed in the United States by Sekisui Diagnostics under the Silaris™ brand. Mesa Biotech has also secured a number of strategic agreements for distribution in Europe and Asia. For more information visit http://www.mesabiotech.com.

Share article on social media or email:

Drs. Anthony N. Imudia, Shayne Plosker and Celso Silva of SGF Florida.

Infertility is a time-sensitive disease. While there’s no doubt this pandemic has greatly impacted all of our lives, no one quite knows the impact of lost time like those who struggle to conceive.

TAMPA BAY, Fla. (PRWEB)
May 14, 2020

SGF, a premier fertility and IVF center and home to 85,000 babies, announced today it has resumed its comprehensive suite of fertility procedures and treatment in the Tampa Bay region.

“While this pandemic has tested us, we are resilient and stronger than ever. I’m thrilled to see the many ways our team members and patients have risen to the occasion. Through the work of many, I am happy that we are able again to offer our full spectrum of services to our patients. We are more united in our quest to build families than ever before,” shared Celso Silva, M.D., M.S., Medical Director of SGF Tampa Bay.

SGF Fertility Treatments Now Available in Florida

Diagnostic testing, ovulation induction (OI), intrauterine insemination (IUI), In Vitro Fertilization (IVF), frozen embryo transfers (FET), donor egg treatment, and oncofertility preservation have all resumed. Patients seeking fertility consult with an SGF physician may do so using a secure, private video consult.

“Our practice is committed to ensuring the safety of our patients and staff. So while this is not business as usual, we’re thrilled we were able to establish effective care solutions that help people seeking to build their family to continue, while doing so in a safe environment,” said Shayne Plosker, M.D., of SGF Tampa Bay.

Read more about SGF’s safety protocols.

SGF Tampa Bay Makes Treatment Affordable

SGF Tampa Bay participates with a variety of insurance networks and offers innovative financial programs, including a 100% refund guarantee program. This exclusive program provides patients with the opportunity to pay a fixed amount for up to six fresh IVF or donor egg cycles and any subsequent frozen embryo transfers (FETs). SGF provides a full refund in the event the patient does not take home a baby.

SGF Tampa Bay also offers a Shared Help Discount Program, an income-based program that offers a discount on most treatments and procedures, the Military Discount Program, which offers active U.S. military and reservists a discount off qualifying self-pay rates, and a Shared Donor Egg Program, which reduces the cost of donor egg treatment by up to 50 percent when sharing egg donors with other patients.

“Infertility is a time-sensitive disease. While there’s no doubt this pandemic has greatly impacted all of our lives, no one quite knows the impact of lost time like those who struggle to conceive. Our community is so grateful for the enormous efforts made by frontline healthcare professionals, and all those throughout the state who are doing their part to flatten the curve. Now with new guidance in place, we are able to continue to provide essential fertility care to new and existing patients,” said Anthony N. Imudia, M.D., of SGF Tampa Bay.

SGF Tampa Bay is accepting new patients. Call 1-877-761-1967 or submit this brief form to schedule a virtual physician consult. SGF Tampa Bay has offices in Tampa, Brandon, and Wesley Chapel, as well as secure telemedicine consultations.

About Shady Grove Fertility (SGF)

SGF is a leading fertility and IVF center of excellence with more than 85,000 babies born and counting. With 38 locations throughout FL, GA, MD, NY, PA, VA, D.C., and Santiago, Chile, we offer patients virtual physician consults, individualized care, accept most insurance plans, and make treatment affordable through innovative financial options, including treatment guarantees. More physicians refer their patients to SGF than any other center. Call 1-888-761-1967 or visit ShadyGroveFertility.com.

Share article on social media or email:

Encompass Group, LLC

Offering scrub sets to as many area hospitals as possible that could receive them right now is our way of continuing to try to make a difference. We’re all in this together.

MCDONOUGH, Ga. (PRWEB)
May 14, 2020

In special recognition of the invaluable role of Georgia nurses during the COVID-19 crisis and in honor of the Year of the Nurse, Nurses Month, and Nurses Week, Encompass Group, LLC today announced recent gifts of professional apparel to seven nearby hospitals. Each of the receiving facilities is in the vicinity of the company’s McDonough, GA corporate headquarters. Between mid-April and the first week of May, approximately 1,200 sets, total, of donated scrubs were delivered to Jasper Memorial Hospital, Wellstar Kennestone Hospital, Medical Center Navicent Health, Piedmont Henry Hospital, Grady Memorial Hospital, Northside Hospital, and Phoebe Putney Memorial Hospital.

Most of the deliveries were made personally by Encompass Group, LLC staff, including Chief Executive Officer John Wood, Executive Vice President – Operations Andrew Boyd, Vice President and General Manager – Professional Healthcare Apparel Deanna Leonard, Senior Managing Director – Corporate Services Marty Mappes, Managing Director – Product Management Michelle Daniels, Merchandise Manager – Professional Healthcare Apparel Kristy Mosel. To capture these unique community interactions, the company has added photos and other content to the page, Encompass Cares.

In response to a donation received, Jasper Health Services, Inc. Administrator Jan Gaston said, “We thank Encompass Group for providing scrubs for the recently constructed dedicated COVID unit at Jasper Memorial Hospital. Having uniforms for the staff to wear while working reduces the risk of our team exposing family members and others to the virus. The safety and wellness of our staff is one of our highest priorities. A special thanks to Andrew Boyd for quickly responding to our request.”

Navicent Health Chief Nurse Executive and Medical Center Navicent Health Chief Nursing Officer Tracey Blalock RN, MSN, MBA, NEA-BC, stated, “We would like to thank Encompass Group for their donation of scrubs to Navicent Health. We were so thrilled to have their support during this critical situation. This generous donation will truly make the difference for many of our staff; we are extremely grateful!”

Northside Clinical Supply Chain Manager Kathy James, RN, said, “In recent weeks, our partners have offered us overwhelming support in the form of PPE, linens, and other shows of appreciation. It means more than any words could express. On behalf of Northside Hospital and all of our staff, thank you.”

“We cannot thank the individuals and organizations who have supported our hospital during this crisis enough,” said Paula Butts, Chief Nursing Officer at Piedmont Henry Hospital. “This is an unprecedented time for hospitals and healthcare workers and these generous donations allow us to continue our mission of caring for our community.”

Wellstar Foundation Director of Strategic Giving Lisa Mello declared, “Wellstar caregivers are the heroes of our health system and the community has been incredibly supportive of our team members across all of our service areas. The outpouring of support has touched our team members. From generous donations of scrubs for our healthcare workers, to donations of meals, masks, messages of support, and contributions to the Wellstar Foundation’s COVID-19 Relief Fund, every action has been heartfelt.”

Remarked Encompass Group, LLC Chief Executive Officer John Wood, “We always enjoy celebrating and giving back to those that care for patients year after year. This year, more than ever, our team wanted to say a special thank you for the tireless work that neighboring nurses are doing to keep all of us safe and well during this pandemic. While we could not reach everyone, we want you all to know that we greatly appreciate all that you do every day and especially during this health crisis. You are making such a difference in our community and we are humbled to be able to provide some help during this time.”

Encompass Group, LLC, Vice President and General Manager – Professional Healthcare Apparel Deanna Leonard, added, “Encompass Group apparel brands are made with healthcare provider safety and comfort in mind. It’s literally in our mission to care about the healthcare community, as they care for us. In the midst of this COVID-19 crisis, we’ve become acutely aware of not just the nation’s struggles, but of those occurring close to home. Offering scrub sets to as many area hospitals as possible that could receive them right now is our way of continuing to try to make a difference. We’re all in this together.”

To see photos and other content related to Encompass Cares, please visit https://www.encompassgroup.com/encompass-cares. To learn more about Encompass Group, LLC, please visit https://www.encompassgroup.com.

ABOUT ENCOMPASS GROUP, LLC

Encompass Group, LLC is one of the world’s leading manufacturers and marketers of reusable textiles, professional apparel, and disposable and single-use medical products. Encompass Group believes that every patient, resident, caregiver, and family member should feel safe and comfortable in today’s healthcare environments. Encompass Group enhances the healthcare experience by developing innovative products that are reliably delivered and cost-effective for all providers. Encompass Group serves the acute-care, long-term, and senior-care markets, retail healthcare and hospitality apparel markets, and government operations markets. For more information about Encompass Group, LLC, please visit https://www.encompassgroup.com.

Follow Encompass Group, LLC on LinkedIn at https://www.linkedin.com/company/encompass-group-llc/ (@encompass-group-llc); Twitter at https://twitter.com/EncompassGrpLLC (@EncompassGrpLLC); Facebook at https://www.facebook.com/EncompassGrpLLC (@EncompassGrpLLC); and YouTube at https://www.youtube.com/user/EncompassGroupLLC.

# # #

Share article on social media or email:

“We are proud to name Dr. John Pettit as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
May 14, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that John Pettit, M.D., Bellingham Urology Group PLLC in Bellingham, WA, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Pettit has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. John Pettit as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose

For Teleflex Incorporated:

Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504 nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction

1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email: